Analysts rate Tilray with a consensus Buy rating and a 12-month average Target Price of $16.79 per share.
Morningstar maintained Tilray Inc. with a Buy rating and lowered the target to $16 from $18 on the company’s stock.
Based on the Tilray Inc. stock forecasts from 3 analysts, the average analyst target price for Tilray Inc. is CAD 16.79 over the next 12 months. Tilray Inc.’s average analyst rating is Buy. Stock Target Advisor’s own stock analysis of Tilray Inc. is Slightly Bearish, which is based on 2 positive signals and 3 negative signals. At the last closing, Tilray Inc.’s stock price was CAD 7.45. Tilray Inc.’s stock price has changed by -0.34% over the past week, -0.41% over the past month and +0.00% over the last year.
Tilray Brands Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products. It operates through five segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, Wellness Business, and Business Under Development. The company was formerly known as Tilray, Inc. Tilray Brands Inc. was incorporated in 2018 and is headquartered in New York, New York.
What we like:
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
Compared to its sector, this stock has shown top quartile revenue growth in the previous 5 years.
What we don’t like:
Compared to its sector peers on debt to equity, the company is in the bottom half and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Negative cash flow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector.